Insulin (human) recombinant
Biological ActivityEndogenous insulin receptor agonist (Ki = 4.85 nM). Decreases plasma glucose levels, proteolysis, lipolysis and gluconeogenesis and increases glycogen and fatty acid synthesis in vivo.
(Modifications: Disulfide bridge between 6 - 11, 7 -7*, 20 - 19*)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Leney and Tavare (2009) The molecular basis of insulin-stimulated glucose uptake: signalling, trafficking and potential drug targets. J.Endocrinol. 203 1. PMID: 19389739.
Ou et al (2001) The binding characteristics of insulin-MTX to insulin receptor. Hua.Xi.Yi.Ke.Da.Xue.Xue.Bao. 32 538. PMID: 12528542.
Torlinska et al (2000) Age dependent changes of insulin receptors in rat tissues. J.Physiol.Pharmacol. 51 871. PMID: 11220495.
If you know of a relevant reference for Insulin (human) recombinant
expressed in yeast please let us know.
Citations are publications that use Tocris products. Selected citations for Insulin (human) recombinant
expressed in yeast include:
Stretton et al (2015) GSK3-mediated raptor phosphorylation supports amino-acid-dependent mTORC1-directed signalling. Br J Pharmacol 470 207. PMID: 26348909.
Do you know of a great paper that uses Insulin (human) recombinant
expressed in yeast from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Insulin (human) recombinant, expressed in yeast, supplier, Endogenous, peptide, agonists, IGF, Receptors, nsulin-like, Receptor, Tyrosine, Kinases, RTKs, Tocris Bioscience, Insulin and Insulin-like Receptor Activator products
Find multiple products by catalog number
New Products in this Area
Potent and selective PDGFR inhibitorGSK 1363089
Potent inhibitor of MET, VEGFR2, Ron and AXLPF 06273340
Potent and selective pan-Trk inhibitor; peripherally restricted
August 20 - 24, 2017
Paris , France